Rombotis Spiro George 4
4 · Cyclacel Pharmaceuticals, Inc. · Filed Jan 7, 2019
Insider Transaction Report
Form 4
Rombotis Spiro George
DirectorPresident & C.E.O.
Transactions
- Award
Option
2019-01-03+15,625→ 15,625 totalExercise: $1.74Exp: 2027-12-29→ Common Stock (15,625 underlying) - Award
Option
2019-01-03+14,375→ 14,375 totalExercise: $1.56Exp: 2028-02-22→ Common Stock (14,375 underlying) - Award
Option
2019-01-04+508,198→ 508,198 totalExercise: $0.71Exp: 2029-01-04→ Common Stock (508,198 underlying)
Footnotes (4)
- [F1]These securities are exercisable over a three-year period, with 1/36 of the options granted vesting on a monthly basis.
- [F2]These securities were granted as part of the Issuer's annual compensation review to executive officers.
- [F3]On December 29, 2017, Spiro Rombotis was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on January 3, 2019, resulting in the vesting of the option as to 15,625 shares.
- [F4]On February 22, 2018, Spiro Rombotis was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on January 3, 2019, resulting in the vesting of the option as to 14,375 shares.